Business description
Nektar Therapeutics is a research-based, development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. The R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.
Management board & Supervisory board
| CEO |
| Howard W. Robin |
| Management board |
| Gil M. Labrucherie, Brian L. Kotzin, M.D., Dr. Dimitry S.A. Nuyten, Dr. Jonathan Zalevsky, Dr. Kevin Brodbeck, Dr. Urte Gayko, Jennifer Ruddock, Jilian B. Thomsen, John Northcott, Mark A. Wilson, Mary Tagliaferri, M.D., Robert Bacci |
| Supervisory board |
| Robert B. Chess, Diana M. Brainard, Dr. Myriam J. Curet, Howard W. Robin, Jeff Ajer, Karin Eastham, R. Scott Greer, Roy A. Whitfield |
Company data
| Name: |
Nektar Therapeutics Inc. |
| Address: |
455 Mission Bay Boulevard South,San Francisco, CA 94158, USA |
| Phone: |
+1-415-482-5300 |
| Fax: |
+1-415-339-5300 |
| E-mail: |
-
|
| Internet: |
https://www.nektar.com/ |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
31/12 |
| Free Float: |
- |
| IPO date: |
- |
Investor relations
| Name: |
Vivian Wu |
| IR phone: |
+1-628-895-0661 |
| IR Fax: |
- |
| IR e-mail: |
-
|
